Exelixis (EXEL) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $51.34 -0.02%
EPS Growth %: +13.3%
Financial Fact:
Research and development: 22.98M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +13.3%
Financial Fact:
Research and development: 22.98M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $9.94 million versus the consensus estimate of $8.16 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
